Business Wire

Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy Surgery

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is ...
Business Wire

Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer ...

INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...
Monthly Prescribing Reference

FDA Approves Drug-Device Combo to Detect Residual Cancer After Lumpectomy

Approval was supported by data from a randomized, intra-patient controlled trial, which included patients with confirmed invasive breast cancer, ductal carcinoma in situ, or both. The Food and Drug ...
Morningstar

Lumicell Announces Collaboration with Learn Look Locate to Empower Breast Cancer Patients through Lumpectomy Education

NEWTON, Mass., Dec. 18, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced a new collaboration with ...